<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535609</url>
  </required_header>
  <id_info>
    <org_study_id>REN001-201</org_study_id>
    <nct_id>NCT04535609</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of 24 Week Treatment With REN001 in Patients With Primary Mitochondrial Myopathy</brief_title>
  <acronym>STRIDE</acronym>
  <official_title>A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reneo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reneo Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study&#xD;
      designed to investigate the efficacy and safety of REN001 administered once daily over a&#xD;
      24-week period to patients with PMM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in distance walked during the Walk Test</measure>
    <time_frame>Week 24</time_frame>
    <description>Distance walked in meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 24 in the Modified Fatigue Impact Scale (MFIS) physical sub-scale score</measure>
    <time_frame>Week 24</time_frame>
    <description>Physical Scale 0-36 scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>7 point scale: Very much improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, Very much worse</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of adverse events, serious adverse events, and withdrawals due to adverse events</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Number and Severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in number of sit to stands in the sit to stand test</measure>
    <time_frame>Week 24</time_frame>
    <description>Individual counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in number of steps</measure>
    <time_frame>Week 24</time_frame>
    <description>Step count from pedometer</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Patient Global Impression of Severity (PGIS) score</measure>
    <time_frame>Week 24</time_frame>
    <description>5 point scale: Absent, Mild, Moderate, Severe, Very Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in MFIS total, cognitive and psychosocial sub-scale scores</measure>
    <time_frame>Week 24</time_frame>
    <description>Total MFIS 0-84, cognitive 0-40, psychosocial 0-8</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Brief Pain Inventory pain severity and pain interference scores</measure>
    <time_frame>Week 24</time_frame>
    <description>Numerical rating scale 0-10</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Mitochondrial Myopathy</condition>
  <arm_group>
    <arm_group_label>REN001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REN001</intervention_name>
    <description>Once daily</description>
    <arm_group_label>REN001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects age 18 years or older with PMM as defined by the International Workshop:&#xD;
             Outcome measures and clinical trial readiness in primary mitochondrial myopathies in&#xD;
             children and adult (Mancuso et al 2017).&#xD;
&#xD;
          2. A confirmed PMM diagnosis due to known pathogenic gene mutation or deletion of the&#xD;
             mitochondrial genome. The Sponsor may authorize local genetic testing at Screening, if&#xD;
             required, but results must be available prior to randomization of the subject.&#xD;
&#xD;
          3. Documented PMM primarily characterized by exercise intolerance or active muscle pain.&#xD;
&#xD;
          4. Subjects must be ambulatory and able to perform the walking tests independently&#xD;
             (walking aids are allowed).&#xD;
&#xD;
          5. Have no changes to any therapeutic exercise regimen within 30 days prior to Day 1 and&#xD;
             be willing to remain on the same therapeutic exercise regimen for the duration of the&#xD;
             study.&#xD;
&#xD;
          6. Females should be either of non-child-bearing potential or must agree to use highly&#xD;
             effective methods of contraception from Screening through to 30 days after last dose&#xD;
             in the study. Males with partners who are WOCBP must also use contraception.&#xD;
&#xD;
          7. Concomitant medications (including supplements) must be stable for at least 1 month&#xD;
             prior to enrolment and throughout participation in the study.&#xD;
&#xD;
          8. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subject has been informed of all pertinent aspects of the study.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Participation in a prior REN001 (previously known as HPP-593) study.&#xD;
&#xD;
          2. Currently taking or anticipated to need a PPAR agonist during the study.&#xD;
&#xD;
          3. Subjects with bone deformities or motor abnormalities other than related to the&#xD;
             mitochondrial myopathy that may interfere with the outcome measures.&#xD;
&#xD;
          4. Clinically significant kidney disease or impairment calculated as eGFR Grade 2 or&#xD;
             above &lt;60ml/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             (CKD-EPI) creatinine equation at Screening.&#xD;
&#xD;
          5. Clinically significant liver disease or impairment of AST or ALT Grade 2 or above&#xD;
             (&gt;2.5 x ULN), or Total bilirubin &gt; 1.6 x ULN or &gt;ULN with other signs and symptoms of&#xD;
             hepatotoxicity at Screening.&#xD;
&#xD;
          6. Subjects with uncontrolled diabetes and/or a Screening HbA1c of â‰¥11%.&#xD;
&#xD;
          7. Evidence of significant concomitant clinical disease that may need a change in&#xD;
             management during the study or could interfere with the conduct or safety of this&#xD;
             study. (Stable well-controlled chronic conditions such hypercholesterolemia,&#xD;
             gastroesophageal reflux, or depression under control with medication (other than&#xD;
             tricyclic antidepressants), are acceptable provided the symptoms and medications would&#xD;
             not be predicted to compromise safety or interfere with the tests and interpretations&#xD;
             of this study.)&#xD;
&#xD;
          8. Subjects with a history of cancer. A history of in situ basal cell carcinoma in the&#xD;
             skin is allowed.&#xD;
&#xD;
          9. Clinically significant cardiac disease and/or clinically significant ECG abnormalities&#xD;
             such as 2nd degree heart block, symptomatic tachyarrhythmia or unstable arrythmia&#xD;
             (right bundle branch block, left fascicular block and long PR interval are not&#xD;
             excluded) that in the opinion of the Investigator should exclude the subject from&#xD;
             completing exercise tests.&#xD;
&#xD;
         10. Evidence of hospitalization for rhabdomyolysis within the year prior to enrolment.&#xD;
&#xD;
         11. Pregnant or nursing females.&#xD;
&#xD;
         12. History of sensitivity to PPAR agonists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amel Karaa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital (MGH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Coordinator</last_name>
    <phone>+44 (0) 1304 809360</phone>
    <email>clintrialinfo@reneopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mhammack@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Haas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Myology Institute, University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>amanda.cowsert@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>S.H. Subramony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>elkelly@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michio Hirano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>htonni@akronchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Bruce H Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>nguyens2@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Marni Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>michele.graham@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Vockley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas SouthWestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>osniel.gonzalezramos@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Salman Bhai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for the Treatment of Pediatric Neurodegenerative Disease, University of Texas McGovern Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>donovan.calvert@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Kay Koenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Fabienne.Edemahildebrand@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Carolyn Sue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PARC Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roula Ghaoui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Health Care Bethlehem</name>
      <address>
        <city>Parkdale</city>
        <state>Victoria</state>
        <zip>3195</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bethlehem.research@calvarycare.org.au</email>
    </contact>
    <investigator>
      <last_name>Christine Wools, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000B</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Kristl.Claeys@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Kristl Claeys, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adult Metabolic Diseases Clinic, Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mezei@mail.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Michelle Mezei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hana.kolarova@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Hana Kolarova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>john.vissing@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>John Vissing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn Clinic and Polyclinic for Neurology</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cornelia Kornblum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center of the University of Munich Friedrich Baur Institute at the Neurological Clinic and Polyclinic</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Klopstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Insitute of Genomics and Rare Disorders</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria J Molnar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of PÃ©cs Clinical Centre, Department of Neurology</name>
      <address>
        <city>PÃ©cs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jozsef Janszky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana Dipartimento di specialita' mediche UOC Neurologia</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>michelangelo.mancuso@unipi.it</email>
    </contact>
    <investigator>
      <last_name>Michelangelo Mancuso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Auckland</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kay.yeoman@auckland.ac.nz</email>
    </contact>
    <investigator>
      <last_name>Richard Roxburgh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>JCMILISE@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Jose Millisenda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cdgonzalez@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Cristina Dominguez Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i PolitÃ¨cnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>unidadneuromuscularlafe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nuria Muelas Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Myopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

